Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
10 September 2021 | Story Leonie Bolleurs | Photo Sonia Small (Kaleidoscope Studios)
Dr Molapo Qhobela, the newly appointed Vice-Rector: Institutional Change, Strategic Partnerships and Societal Impact, will be speaking at the International Summit on the Sustainable Development Goals (SDGs) in Africa 2021.

Dr Molapo Qhobela, the newly appointed Vice-Rector: Institutional Change, Strategic Partnerships and Societal Impact at the University of the Free State (UFS), will be speaking at the three-day International Summit on the Sustainable Development Goals (SDGs) in Africa 2021. The summit will take place as follows:

Date: 13-15 September 2021 
Platform: A virtual gathering (register for the upcoming virtual summit)

Together with a wide array of thought leaders, including specialists, senior researchers, CEOs/directors, and the top structures of international organisations, he will address and engage with an audience of academics, practitioners, government authorities, representatives from civil society, and donors and sponsors from across the globe on the topic Partnerships for impact in Africa (session on 15 September from 12:30 to 14:00).

According to the host of the event, the University of Cape Town, the key aim of the International Summit on the SDGs in Africa is to mobilise collaborative efforts that will accelerate African-led activities in support of achieving the African Union's Agenda 2063 and the United Nations Sustainable Development Goals (SDGs) – a shared blueprint for working towards global peace and prosperity by 2030. The summit is also designed to identify concrete opportunities for research collaboration that will accelerate the achievement of the SDGs and Agenda 2063.

The talks, panel discussions, workshops, and breakout sessions will revolve around clear steps for implementation.

For more information, visit: http://www.sdgsafricasummit.uct.ac.za/

Background of Dr Molapo Qhobela

Dr Qhobela’s leadership and strategic direction have been sought by several large and complex organisations during his career. He is the immediate former Chief Executive Officer (CEO) of the National Research Foundation, and also the former Chair of the Global Research Council as well as the Agricultural Research Council. He is currently the Chairperson of the Tertiary Education and Research Network of South Africa. Dr Qhobela holds a PhD in Plant Pathology from the Kansas State University in the United States of America.

News Archive

New research informs improved treatment of brain inflammation
2017-10-13

Description: Sebolai and Ogundeji Tags: Microbiologist, Dr Adepemi Ogundeji,  

Dr Adepemi Ogundeji, researcher in the Department of Microbial,
Biochemical and Food Biotechnology at the
University of the Free State,
and Dr Olihile Sebolai,
her study leader from the same department.
Photo: Charl Devenish



Microbiologist Dr Adepemi Ogundeji has uncovered a new use for an old medicine that can potentially save lives and money. Under the guidance of her study leader, Dr Olihile Sebolai, Dr Ogundeji set out to fight a fungal disease caused by Cryptococcus neoformans. Drs Ogundeji and Sebolai are from the University of the Free State Department of Microbial, Biochemical and Food Biotechnology. 

Dr Ogundeji is passionate about education. “My aim will always be to transfer knowledge and skills in the microbiology field,” she said. “Dr Ogundeji’s study is celebrated in that it found a new purpose for existing medicines. An advantage of repositioning old medicines is by-passing clinical trials, which sometimes take 20 years, and the safety of such medicines is already known,” Dr Sebolai, explained.

Cryptococcus infections are difficult to control and often lead to brain inflammation. In layman’s terms: “Your brain is on fire”. People with HIV/Aids are especially vulnerable, surviving only about three months without treatment. Such patients may present with a Cryptococcus-emergent psychosis, and some with an out-of-control inflammatory condition when initiated on ARVs. 

Dr Ogundeji found that the clinically recommended dosage of aspirin (anti-inflammatory medicine), and quetiapine (anti-psychotic medicine) is sufficient to control the infection. Her exceptional work was readily published in some of the foremost journals in her field, namely, Antimicrobial Agents and Chemotherapy and Frontiers in Microbiology

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept